

## Dr. Mariano Provencio Pulla MD, PhD

### Present Title and affiliation

#### Primary Appointment

- 2011-**Present** – Head of Medical Oncology Department at Puerta de Hierro University Hospital
- 2011-**Present**. Full Professor of the School of Medicine at Autonomous University of Madrid

#### Adjunct Appointment

- 2012-**Present** –Board member of the Research Institute at Puerta de Hierro University Hospital
- 2012- **Present**- Scientific Director of the Research Institute at Puerta de Hierro University Hospital.



### Office address

Medical Oncology Department. Puerta de Hierro University Hospital  
Calle Manuel de Falla, 1. Majadahonda. Madrid. 28222

### Education & Training

#### Degree-Granting Education

Alcalá University. Madrid. Spain.

#### Postgraduate Training

1989-1992- Medical Oncology Fellowship, Oncology Department. Puerta de Hierro University Hospital

1997- Ph D, Alcalá University. Madrid, Spain.

2003- *Lymphomas and Thoracic Oncology* -**Memorial Sloan-Kettering Cancer Center de Nueva York (USA)**

2004- **Hospital Paul Brousse de Villejuif (Paris-Francia)**

2006- *Lymphoma Department* **MD Anderson Cancer Center** de Universidad de **Houston** Texas. (USA)

2009. *Malignancy Hematology Department. Hospital Lee-Moffitt Cancer Center, Tampa. (USA)*

2013. *Lymphomas Department. MD Anderson Cancer Center de Universidad de Houston Texas. (USA)*

## Board Certifications

1995- European Oncology Board Certificate awarded by the European Society for Medical Oncology (ESMO).

## Experience/Service

### Academic Appointments

- 1995-2010- Honorary Professor & Teaching Clinical Collaborator of the School of Medicine at Autonomous University of Madrid

### Other Appointments/Responsibilities

- 1993-2011- Associate Physician in Oncology Department
- 2007- **Present**- President of the Spanish Lymphoma Oncology Group (GOTEL)
- 2002- **Present**. Board of the Spanish Lung Cancer Group. (SLCG)
- 2010-**Present**. Board of Publishing Group-European Society for Medical Oncology (ESMO)

### Institutional Committee Activities

- 2000-2011. Member of the Clinical Trials Commission
- 2010-**Present**-Member of the Scientific Committee of the Research Foundation

### Research activity

- Publication list :  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=provencio+M>
- **H Index: 31**

## International Publications

1. Pneumomediastinum after belching. De la Fuente J., Román F., Hernáez J., **Provencio M.**, Martínez L. de Letona.  
*The Lancet* 1990;1:1390. (FI: 11,793)

2. Intracranial Tuberculoma: Paradoxical expansion during medical treatment. **Provencio M.**, De la Fuente J., Hernández J., Román F., Martínez L. de Letona. *Postgraduate Medical Journal* 1992; 68: 487-488. (FI:1,3 )
3. Multiple Primary Tumors and Familial Cancers. A case report. **Provencio M.**, Bonilla F., López Vega J.M., Lacasta A., España P. *Tumori* 1993;79(4):273-274. (FI: 0,75)
4. Malignant Fibrous Histiocytoma of the Spleen and Chronic Myelogenous Leukemia: A case report. Bonilla F, **Provencio M.**, Fernandez E, España P. *Oncology* 1994;51:465-466. (FI: 2,790)
5. Cerebral infarction after cisplatin based chemotherapy. **Provencio M.**, Bonilla F., Lacasta A, España P. *Postgraduate Medical Journal* 1994; 70(8):525-526.
6. Primary osteosarcoma of the meninges. Bonilla F, **Provencio M**, Salas C, España P. *Annals of Oncology*1994; 5(10): 965-966 (F I: 4,31)
7. Breast angiosarcoma after radiation therapy. **Provencio M.**, Bonilla F., España P. *Acta Oncol* 1995 34, 969:7 (FI: 0,747)
8. Prognostic implications of loss of heterozygosity in the 17q21 region in breast cancer. Gomedio B, Silva JM, **Provencio M**, García JM, García-Patiño E, García Andrade C, Carretero L, España P, Bonilla F. *International Journal of Oncology* 1997; 10 (3): 659-663.(FI: 1,040)
9. BRCA1 mutations in patients with familial risk of breast cancer. García-Patiño E, Gomedio B, Silva JM, García JM, **Provencio M**, España P, F

Bonilla F.

*Acta Oncol* 1998; 37(3): 299-300 (FI: 0,747)

10. Breast cancer and cutaneous vasculitis. Arzuaga JA, **Provencio M**, Bonilla F, Salas C, España P.

*Eur J Gynae Oncol* 1995; 14:253-257

11. Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. García- Patiño E, Gomedio B, Silva JM, García JM, **Provencio M**, Pérez-Carrión R, et al.

*International Journal of Oncology* 1998; 13: 275-279 (FI: 1,299)

12. Loss of heterozygosity in the region including the BRCA1 gene on chromosome 17q in colon cancer. García-Patiño E, Gomedio B, Lleonart M, Silva JM, García JM, **Provencio M**, et al.

*Cancer Genet Cytogenet* 1998; 103:1-5 (FI: 1,756)

13. Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. García-Patiño E, Gomedio B, **Provencio M**, et al.

*J Clin Oncol* 1998;16(1):115-20 (FI: 11,8)

14. Abnormal frequencies of alleles in polymorphic markers of the 17q21 region is associated with breast cancer. Silva JM, García JM, González R, Domínguez G, Jareño E, Palacios J, Navarro F, **Provencio M**, España P, Bonilla F.  
*Cancer Letters* 1999; 138: 209-215 (FI: 1,514)
15. Combined losses of heterozygosity in the BRCA1 and BRCA2 regions in breast cancer. Silva JM, García JM, González R, Domínguez G, Palacios J, Gallego I, Provencio M, España P, Bonilla F.  
*Breast Cancer Res Treat* 1999; 53: 9-17 (FI:4.69)
16. Low incidence of germline BRCA2 gene mutations among Spanish breast cancer patients. Gomedio B, Silva JM, García JM, **Provencio M**, España P, Bonilla F.  
*Oncology* 1999; 57: 173-174 (FI: 2,589)
17. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. JM Silva, R González, **Provencio M**, G Domínguez, JM García, I Gallego, Palacios J, España P, Bonilla F.  
*Breast Cancer Res Treatment* 1999; 53:9-17 (FI: 4,69)
18. Comparison of long-term mortality in Hodgkin's disease with the general population. **Provencio M**, García-López FJ, et al.  
*Annals of Oncology* 1999; 10: 1199-1205 (FI: 4,31)
19. Presence of tumor in DNA plasma of breast cancer patients: clinicopathological correlations. Silva JM, Domínguez G, García JM, González R, **Provencio M**, et al.  
*Cancer Research* 1999; 59: 3251-3256 (FI: 8,614)
20. Aberrant DNA Methylation of the p16<sup>INK4a</sup> gene in plasma DNA of breast cancer patients. Silva JM, Domínguez G, Villanueva MJ,

- González R, García JM, Corbacho C, **Provencio M**, España P, Bonilla F.  
*British Journal Cancer* 1999; 80(8): 1262-1264 (FI: 3,281)
21. Detection of Loss of heterozygosity at RAD51, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. González R, Silva JM, Domínguez G, García JM, Martínez G, Vargas J, **Provencio M**, España P, Bonilla F.  
*Br J Cancer* 1999; 81(3): 503-9 (FI: 3,281)
22. Allelic loss of the PTEN region (10q23) in breast carcinoma of poor pathophenotype. García JM, Silva JM, Domínguez G, González R, Navarro MA, Carretero L, **Provencio M**, España P, Bonilla F.  
*Breast Cancer Res Treat* 1999; 57:237-243 (FI: 2,800)
23. Phase II study of Ifosfamide plus Vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. Lobo F, Frau A, Barnadas A, Méndez M, Lizón J, **Provencio M** et al.  
*Cancer Chemother Pharmacol* 1999; 16; 44(7): S5-S8 (FI: 2,081)
24. Testicular Germ Cell tumors and Down Syndrom. Villanueva MJ, Navarro F, Sánchez A, **Provencio M**, Bonilla F, España P.  
*Tumori* 2000; 86:431-433 (FI:0,75)
25. Absence of point mutations at codon 17 of the Mdm2 gene (serine 17) in human primary tumors. Silva J, Silva JM, Domínguez G, García M, Rodríguez O, García-Andrade C, Cuevas J, **Provencio M**, España P, Bonilla F.  
*Mutation Research* 2000; 449: 41-45 (FI: 4,63)
26. Microsatellite alterations and TP53 mutations in plasma DNA of small cell lung cancer patients: Follow-up study and prognostic significance.

- González R, Silva JM, Sánchez A, Domínguez G, García JM, Gi Chen X, Stroum M, **Provencio M**, España P, Anker P, Bonilla F. *Annals of Oncology* 2000;11: 1097-1104 (F I: 5,31)
27. DNA damage after chemotherapy correlates with tumor response and survival in small cell lung cancer patients. Silva JM, García JM, Domínguez G, Silva J, Rodríguez R, Portero JL, Corbacho C, **Provencio M**, España P, Bonilla F. *Mutation Research* 2000; 30: 65-71 (FI:4,63)
28. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Silva JM, García JM, Silva J, Miralles C, Cantos B, Coca S, **Provencio M**, España P, Bonilla F. *Ann Surg Oncol* 2002; 9(1): 71-6(FI: 4,643)
29. Hodgkin's disease: correlation between causes of death at autopsy and clinical diagnosis. **Provencio M**, España P, Salas C, et al. *Annals of Oncology* 2000;11: 59-64 (F I:5,31)
30. Metastatic renal cell carcinoma to the head and neck area. Navarro F, Vicente J, Villanueva MJ, Sánchez A, **Provencio M**, España P. *Tumori* 2000; 86(1): 88-90 (FI: 0,75)
31. Clinicopathological characteristics of breast carcinomas with allelic loss in the p73 region. Domínguez G, Silva J, Silva JM, García JM, Miralles C, Jareño E, **Provencio M**, España P, Bonilla F. *Breast Cancer Research and Treatment* 2000; 63(1): 17-22 (FI: 2,815)
32. Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. García JM, González R, Silva JM, Domínguez G, Sánchez Vegazo I, Gamallo C, **Provencio M**, et al. *British Journal of Cancer* 2000; 82: 1183-1185 (FI: 3,909)

33. Different expression of p14ARF defines two groups of breast carcinomas regarding p73 expression and p53 mutational status. Dominguez G, Silva J, Silva JM, García JM, Larrondo FJ, Vargas J, Sanfrutos J, **Provencio M**, España P, Bonilla F.  
*Genes Chromosomes Cancer* 2001;31(2):99-106 (FI: 4,416)
34. Hodgkin's disease: unsuspected minimal activity in patients that die from causes other than tumoral progression. **Provencio M**, España P, et al.  
*Leukemia-Lymphoma* 2001; 42(4): 661-664 (FI: 2,39)
35. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Silva J, Domínguez G, Silva JM, García JM, Gallego I, Corbacho C, **Provencio M**, España P, Bonilla F.  
*Oncogene* 2001; 20: 4586-4590 (FI: 6,737)
36. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Cutuli B, Borel C, Dhermain F, Magrini SM, Wassermann TH, Bogart JA, **Provencio M**, et al.  
*Radiation Oncology* 2001 ; 59(3):247-55 (FI: 2,803)
37. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Silva JM, Domínguez G, Silva J, García JM, Sánchez A, Rodríguez O, **Provencio M**, España P, Bonilla F.  
*Clinical Cancer Res* 2001; 7:2821-2835 (FI: 5,076)
38. Wild type p73 overexpression and high-grade malignancy in breast cancer. Domínguez G, Silva JM, Silva J, García JM, Sánchez A, Navarro A, Gallego I, **Provencio M**, España P, Bonilla F.  
*Breast Cancer Research and Treatment* 2001; 66:183-190 (FI: 2,817)
39. Persistence of tumor DNA in plasma of breast cancer patients after



- mastectomy. Silva JM, García JM, Domínguez G, **Provencio M**, España P, Bonilla F.  
*Annals of Surgical Oncology* 2002; 9(1): 71-76 (FI: 3,639)
40. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Silva JM, Rodríguez R, García JM, Silva J, Domínguez G, **Provencio M**, et al.  
*Gut* 2002;50: 530-534 (FI:8,3)
41. p14ARF promoter Hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Domínguez G, Carballido J, Silva J, Silva JM, García JM, Menéndez J, **Provencio M**, España P, Bonilla F.  
*Clinical Cancer Research* 2002; 8: 980-985 (FI: 5,979)
42. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Silva JM, Silva J, Sánchez A, García JM, Domínguez G, **Provencio M**, et al.  
*Clinical Cancer Res* 2002; 8: 3761-3766 (FI: 5,979)
43. The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone. **Provencio M**, España P, Millán I, Sánchez A, Cantos B, Bonilla F.  
*Leukemia and Lymphoma* 2003; 44(2), 263-268 (FI: 2,399)
44. Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey by the *International Extranodal Lymphoma Study Group*. Zucca E, Conconi A, Sarris AH, Seymour JF, **Provencio M** et al.  
*J Clin Oncol* 2003; 21: 20-27 (FI: 16,8)
45. Cancer antigen 125 associated with multiple benign and malignant

pathologies. Miralles C, Orea M, España P, **Provencio M**, Sánchez A, et al.

*Annals of Surgical Oncology* 2003;10(2): 150-154(FI: 3,130)

46. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. Silva J, Silva JM, Dominguez G, **Provencio M**, et al.

*J Pathol* 2003; 199 (3): 289-97.(FI:5)

47. The topoisomerase II alpha expression correlates with survival patients with advanced Hodgkin's lymphoma. **Provencio M**, Corbacho C, Salas C et al.

*Clin Cancer Res* 2003; (4): 1406-1. (FI: 6,495)

48. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group. Phase III randomised trial. Alberola V, Camps C, **Provencio M**, et al.

*J Clin Oncol* 2003;21: 3207-3213 (FI: 16,8)

49. Intratumoral Heterogeneity in Microsatellite Alterations in BRCA1 and PTEN Regions in Sporadic Colorectal Cancer. Garcia JM, Rodriguez R, Silva J, Munoz C, Dominguez G, Silva JM, Carcereny E, **Provencio M**, España P, Bonilla F.

*Ann Surg Oncol* 2003; 10(8):876-81 (FI: 3,130)

50. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola V, **Provencio M**, Camps C, De Marinis F, Sanchez JJ, Penas R.

*Semin Oncol.* 2003 Aug;30(4 Suppl 10):19-25.(FI: 4,720)

51. Prognostic significance of allelic of BRCA1 gene in colorectal cancer.

- García JM, Rodríguez R, Silva JM, **Provencio M** et al.  
*Gut* 2003; 52: 1756-1763. (FI: 4)
52. Re: The topoisomerase II $\alpha$  expression correlates with survival in patients with advanced Hodgkin's lymphoma. **Provencio M**, España P, Bonilla F, Salas C. *Clin Cancer Res* 9: 5430-5431, 2003. (FI: 8,395)
53. Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomas. Peña C, García JM, Domínguez G, Silva J, **Provencio M**, et al.  
*Genes, Chromosomes and Cancer* 39: 257-262, 2004. (FI: 4,276)
54. Gemcitabine in multi-resistant non-hodgkin lymphomas. Carcereny E, España P, **Provencio M**.  
*Tumori* 90: 360-361, 2004. (FI:0,75)
55. Prognostic factors in Hodgkin's disease. **Provencio M**, España P, Millan I, et al. *Leukemia & Lymphoma* 45: 1133-1139, 2004. (FI: 2,347)
56. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Rosell R, Danenberg KD, Alberola V, Bepler G, Sánchez JJ, Camps C, **Provencio M**, et al. *Clin Cancer Res* 2004, 15; 10(4): 1318-25. (FI: 5,623)
57. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. García JM, Silva J, Peña C, **Provencio M**, et al.  
*Genes Chromosomes Cancer* 2004, 41: 117-24. (FI: 4,276)
58. Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. García V, Silva, Domínguez G, García JM,

- Provencio M**, et al.  
*Mutat Res* 2004, 4; 554: 215-21. (FI: 4,72)
59. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated non-small-cell lung cancer: a Spanish Lung Cancer group trial. Camps C, Massutti B, Jimenez A, **Provencio M**, et al.  
*Ann Oncol* 2006, Mar; 17(3):467-472. (FI: 4,31)
60. Rapid-infusión Rituximab in lymphoma treatment. **Provencio M**, Cerdeira S, Sánchez A; Bonilla F, España P.  
*Ann Oncol* 2006, Jun, 17 (6): 1027-8 (FI: 4,31)
61. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classical Hodgkin lymphoma. Sánchez Aguilera A, Montalbán C, De la cueva P, Sánchez Verde L, Morente MM; García Cosio M, Garcia Laraña J, Bellas C, **Provencio M**, Romagosa V, Fernandez Sevilla A, Menarguez J, Sabin P, Mestre MJ, Mendez M, Fresno MF, Nicolas C, Piris MA, García JF.  
*Blood* 2006 Mar 21, 15: 108(2): 662-8. (FI: 10,13)
62. Extracellular tumor DNA in plasma and overall survival in breast cancer patients. [Garcia JM, Garcia V, Silva J, Pena C, Dominguez G, Sanchez A, Sanfrutos L, Provencio M, .](#)  
*Genes Chromosomes Cancer*. 2006 Jul;45(7):692-701. (FI: 3,937)
63. Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, **Provencio M**, Bonilla F.  
*Clin Cancer Res*. 2006 Apr 1;12(7 Pt 1):2095-100 (FI: 5,71)
64. Association between virus C and non-Hodgkin Lymphoma. **Provencio M**, Sánchez A; Bonilla F, España P.

*J Clin Oncol* 2006 Jul 20; 24(21): 3513. (FI:16,5)

65. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Silva J, García JM, Peña C, García V, Domínguez G, Suárez D, Espinosa R, **Provencio M**, España P, Bonilla F. *Clin Cancer Res* 2006; 1;12 (23):6929-36. (FI: 5,71)
66. Customizing cisplatin-based chemotherapy on quantitative excision repair cross-complementing 1 mRNA expression: phase III randomized trial in non-small-cell lung cancer. Cobo M, Isla D, Massuti B, Montes A, Sánchez JM, **Provencio M**, et al.  
*J Clin Oncol* 19: 2747-2754, 2007. (FI: 16,5)
67. Long-term survival associated with complete resection following induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: The Spanish Lung Cancer Group 9901 trial. Garrido P, González-Larriba JL, Insa A, **Provencio M** et al.  
*J Clin Oncol* 30: 4736-4742, 2007. (FI: 16,5)
68. R-CHOP-14 in patients with diffuse large-B-cell lymphoma younger than 70 years: A multicentric and prospective study. Rueda A, Sabin P, Rifá J, Llanos M, Gómez Codina J, Lobo F, García-Arroyo L, Herrero J, **Provencio M**, Jara C.  
*Hematol Oncol* 2008. 26: 27-32. (FI:2,18)
69. Analysis of competing risk of causes of death and their variation over different time periods in Hodgkin disease. **Provencio M**, España P, Sánchez A, et al.  
*Clinical Cancer Res*, 2008; 14(16): 5300-5. (FI: 6,25)
70. Fulvestrant activity in the treatment of metastatic prostate cancer. Gasent J, Alberola V, Grande E, **Provencio M**, Juan O.

*Cancer Therapy* 2009; 7: 214-217.

71. Flumazenil in the treatment of dizziness and vegetative symptoms after intravenous infusion of paclitaxel. **Provencio M**, Espinosa R, Sánchez A, España P.

*Onkologie* 2008; 31(4): 203. (FI: 1,22)

72. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Skrzypski M, Jassem E, Taron M, Sánchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, **Provencio M**, Massuti B, Chaib I, Pérez-Roca L, Jassem J, Rosell R.

*Clin Cancer Res* 2008; 14(15): 4794-4799. (FI: 6,25)

73. Estévez LG, Batista N, Sánchez-Rovira P, Velasco A, **Provencio M**, León A, Dómine M, Cruz J, Rodríguez M. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

*Clin Breast Cancer* 2008; 8(2):149-54. (FI: 2,02)

74. Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of an International Phase II Trial. Krzakowski M, **Provencio M**, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P.

*J Thorac Oncol.* 2008 ; 3(9):994-1002. (FI: 4,54)

75. Syncitin: evolution of the human placenta and potential therapeutic target in cancer Gasent Blesa JM, Tattersall I, Konner J, Alberola V, **Provencio M**.

*Cancer Therapy* 2008; 6: 923-930.

76. A review of Langerhans' cell histiocytosis Gasent Blesa JM, **Provencio M**, Laforga Canales J, Alberola Candel V. *Cancer Therapy* 2008, 6: 935-944.
77. Angiogenesis in breast neoplasias: biological basis and clinical relevance. Gasent Blesa JM, **Provencio M**, Laforga Canales J, Grande Pulido E, Alberola Candel. *Cancer Therapy* 2008, 6: 985-992.
78. Lung cancer and treatment in elderly patients: The Achilles Study. **Provencio M**, Camps C, Alberola V, Massutti B, Viñolas N, Isla D, Dómine M, Millán I, Cobo M, Rosell R. *Lung Cancer*. 2009 Oct; 66 (1): 103-6. (FI: 3,5).
79. Considering SRC-ABL as a promising therapeutic target in cancer. Gasent JM, **Provencio M**, Alberola V. *Cancer Therapy* 2009; 200-214
80. Treatment options for metastatic melanoma. A systematic review. Gasent Blesa JM, Grande Pulido E, **Provencio M**, Alberola V. *Cancer Therapy* 2009; 7: 190-201.
81. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression Rosell R, Pérez-Roca L, Sánchez JJ, Cobo M, Morán T, Chaib I, **Provencio M**, et al. *PLoS ONE* 2009, 4(5): e5133. (FI: 4,45)
82. PET and PET-CT in the staging and treatment of Non-Small Cell Lung Cancer. Gasent JM, Alberola V, **Provencio M**. *Cancer Therapy* 2009; 7: 309-319.
83. A prospective study of left ventricle function after treatment with rapid-infusion rituximab in non-hodgkin lymphoma patients. **Provencio M**, A Sánchez, Maximiano C, Cantos, Méndez M, Bonilla F. *Leukemia and Lymphoma*, 2009, Oct; 50(10): 1642-6.(FI: 2,39)
84. Cancer treatments: Can we treasures in back of the sea. **Provencio M**, Sánchez A, Gasent JM, Rosell R. *Clinical Lung Cancer* 2009, 10(4): 295-300. (FI:2,3)
85. A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Sánchez-Espiridión B, Sánchez-Aguilera A, Montalbán C, Martín C, Martínez R, González-

- Carrero J, Poderos C, Bellas C, Fresno MF, Morante C, Mestre MJ, Mendez M, Mazorra F, Conde E, Castaño A, Sánchez-Godoy P, Tomas JF, Morente MM, Piris MA, García JF; Spanish Hodgkin's Lymphoma Study Group. *Clin Cancer Res.* 2009 Feb 15;15(4):1367-75. (FI: 6,4)
86. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A; Spanish Group for the Study of CNS Disease in NHL. *J Clin Oncol.* 2009 Mar 20;27(9):1462-9. Epub 2009 Feb 17. (FI: 16)
87. Differential genetic and functional markers of second neoplasias in Hodgkin's disease patients. Lorenzo Y, **Provencio M**, Lombardía L, Díaz R, Silva J, Herrera M, García JM, Peña C, García V, Romero J, Domínguez G, Bonilla F. *Clin Cancer Res.* 2009 Aug 1;15(15):4823-8. Epub 2009 Jul 21 (FI: 6,4)
88. Screening for epidermal growth factor receptor mutations in lung cancer. Rosell R, Morán T, Queralt C, Porta R, Cardenal F, Camps C, Majen M, López-Vivanco G, Isla D, **Provencio M**, et al. *New England Journal Medicine*, 2009. 361; 958-67.( F.I.: 50)
89. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential? **Provencio M**, De las Peñas R, Camps C, Artal A, Massuti B, Cobo M, FJ Pérez, Sánchez A, Rosell R. *Lung Cancer* 2009. Jun; 68 (3): 415-9.(FI :3,14 )
90. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Carcereny E, Ramírez JL, Sánchez Ronco M, Isla D, Cobo M, Morán T, Aguirre I, Tatsuro Okamoto, Wei J, **Provencio M** et al. *Lung Cancer.* 2009, jun; 68 (3): 491-7.(FI: 3,14)
91. False-positive interpretations in respiratory cytopathology. López A,



- Sánchez A, Yebra M, **Provencio M**. *Clinical Rheumatology* 2009, Sep 26.(FI: 1,59)
- 92.Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. Garcia V, Garcia JM, Silva J, Martin P, Peña C, Dominguez G, Diaz R, Herrera M, Maximiano C, Sabin P, Rueda A, Cruz MA, Rodriguez J, Canales MA, Bonilla F, **Provencio M**. *PLoS One*. 2009 Dec 15;4(12):e8173. (FI: 4,351)
- 93.Rescue treatment with bendamustine in patients with diffuse large B-cell lymphoma. Huelves M, Sánchez AC, Mellor S, **Provencio M**. *Cancer Therapy* 2009; 7: 488-490.
94. Late relapses in Hodgkin's disease: a clinical and molecular study. **Provencio M**, Salas C, Millán I, Cantos B, Sánchez A, Bellas C. *Leukemia & Lymphoma* 2010, sep ; 51 (9): 1686-91. (FI:2,39)
95. Caspase-3a: new prognostic marker for diffuse large b-cel lymphoma in the post-rituximab era. **Provencio M**, Candia A, Martín P, García V, .Sánchez AC, Bellas B. *Leukemia & Lymphoma* 2010, Oct 4. (F.I.:2,39)
96. Skeletal muscle metastasis from non-small cell lung cancer. López-González A, Huelves M, **Provencio M**. *Journal Thoracic Disease* 2012, DOI: 10.3978. ISSN:2072-1439.
- 97.Targeted therapies and radiotherapy integration in lung cancer. **Provencio M**, Sánchez-Ruiz A, Garrido P, Valcárcel F. *Clin Lung Cancer* 2010; 2: 91-97. (F.I: 2.393)
- 98.Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Viñoles N, **Provencio M**, Felip E, Rosell R. *Lung Cancer*. 2010, Jun 3. [Epub ahead of print]. (FI: 3,470)
- 99.Experience with fulvestrant acetate in hormone-resistant prostate cancer patients. Gasent JM, Alberola V, Giner V, Giner-Bosch V, **Provencio M** Laforga JB. *Annals of Oncology*, 2010, May; 21(5): 1131-2. (FI: 4,93)
100. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anton A, Lluch A, Casado A, **Provencio M**,

- Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J, Martin M. *Anticancer Res* 2010 ; 30 (6): 2255-6. (FI: 1,390)
101. Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes. Álvaro T, de la Cruz-Merino L, Henao-Carrasco F, Villar Rodríguez JL, Vicente Baz D, Codes M, de Villena M, **Provencio M**. *Journal of Biomedicine and Biotechnology* 2010 pii: 846872. (FI: 1,86)
102. Old and new insights in the treatment of Thyroid Carcinoma. Gasent JM, Grande E, **Provencio M**, Alberola V, Laforga JB, Grimalt M, Martín P.  
*Journal of Thyroid Research*. 2010. Doi: 10.4061/2010/279468.
103. Melanoma. *From Darkness to promise*. Gasent JM, Grande E, Alberola V, **Provencio M**. *Am J Clinical Oncology* 2011,34 (2): 179-87. (IP: 2, 206 )
104. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-hodgkin's lymphoma patients at high-risk of central nervous system disease in the rituximab era. Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, **Provencio M**, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; (For the Spanish Group for the Study of CNS Disease in NHL). *Eur J Haematol*. 2010, oct; 85(4): 321-8 (FI: 2,34)
105. Vesicle-related microRNAs in plasma of NSCC patients and correlation with survival. Silva J, García V, Zaballos A, **Provencio M**, Lombardía L, Almonacid L, García JM, Dominguez G, Peña C, Díaz R, Herrera M, Varela A, Bonilla F. *Eur Respir J* 2010. Jul 1. (FI:5,54 )
106. Activity of trabectedin in desmoplastic small round cell tumor. López-González A, Cantos B, Tejerina E, **Provencio M**. *Med Oncol* 2010, oct 7 [Epub ahead of print] PMID: 20924717 (FI: 1,22)
107. Trabectedin in Pre-treated Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Phase II Study Evaluating Co-treatment with

- Dexamethasone. Paz-Ares L, López-Pousa A, Poveda A, Balaña C, Bellmunt J, García del Muro J, **Provencio M**, et al. , *New Invest Drugs* 2010, oct 20. (F.I.:3,35)
108. Galán L, Sánchez AC, Cantos B, **Provencio M**. Central nervous system involvement in Hodgkin's lymphoma. *Med Oncol* 2010; oct 14 (F.I.: 1,22)
109. Pre-treatment EGFR T790 M mutation and BRCA1 mRNA expresión in relatinib treated advanced non-small-cell lung cancer patients with EGFR mutations. Rosell R, Molina MA, Costa C, Siminetti S, Gimenez-Capitán A, Bertran-Alamillo J, Mayo C, Morán T, Méndez P, Cardenal F, Isla D, **Provencio M**, Cobo M, et al. *Clin Cancer Res*, 2011. (F.I: 6,4)
110. Screening for epidermal growth factor receptor mutations in lung cancer and Tyrosine-kinase inhibitors. **Provencio M**, Molina MA, Méndez M, Rosell R. *European Journal of Clinical & Medical Oncology*, 2011.
111. New molecular targeted therapies for advanced non-small cell lung cancer. M Méndez, A Custodio, **M Provencio**. *J Thoracic Dis*. 2011. DOI: 10.3978.. (F.I.: 1- preliminar, recién incorporada a Medline)
112. Breast Cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: Analysis of 214 cases. Cutuli B, Kanoun S, Tunon De Lara C, Baron M, Livi L, Levy C, Cohen-Solal-Lenir C, Lesur A, Kerbrat P, **Provencio M**, Gonzague-Casabianca L, Mege A, Lemanski C, Delva C, Lancrenon S, Velten M. *Crit Rev Oncol Hematol*. 2011 Feb 16. (F.I.: 5,269)
113. Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. **Provencio M**, Isla D, Sánchez A, Cantos B. *J Thorac Dis* 2011; 3 DOI 103978. (F.I.: 1- preliminar, recién incorporada a Medline)
114. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. A Custodio, M Méndez, **M Provencio**. *Cancer Treat Rev* 16, 2011. (F.I.: 5, 26).

115. Heterogeneous expresión of Src tyrosine kinases Lyn, Fyn, and Syk in classical Hodgkin lymphoma: prognostic implications. Paloma Matrtin, Clara Salas, **Mariano Provencio**, Victor Abraira, Carmen Bellas. *Leukemia and Lymphoma*, 2011. (F.I.: 2,58)
116. Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin Lymphoma. P Martin, N Gómez-Lozano, S Montes, C Salas, **M Provencio**, C Bellas. *Histopathology* 2011; 59(2): 349-52.(F.I.:3,56)
117. m TOR inhibitor in the treatment of Hodgkin´s lymphoma: a case report. P Ibeas, B Cantos, **M Provencio**. *Blood and Lymphatic Cancer: Targets and Therapy* 2011; 1: 19-22.
118. Clinical practice guidelines for first-line/alter-relapse treatment of patients with follicular lymphoma. López-Guillermo A, Caballero D, Canales M, **Provencio M**, Rueda A, Salar A. *Leuk Lymphoma* 2011, 52(S3): 1-14.(F.I.: 2,58).
119. Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rafael Rosell, Enric Carcereny, Radj Gervais, Prof Alain Vergnenegre, Bartomeu Massuti, , Enriqueta Felip, Ramon Palmero, , Ramon Garcia-Gomez, Cinta Pallares, , Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, , Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier de Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, **Mariano Provencio**, et al. *Lancet Oncology*, 2012, 25 (F.I.: 22.56)
120. Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cáncer Gasent J, Garde J, Laforga JB, Giner V, Alberola A, Soler M, Peris M, Sánchez JL, **Provencio M**, Alberola V.. *J Gastrointest Cancer* 2012; feb 28
121. Trabectedin in patients with advanced non-small-cell lung cáncer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1

- underexpression and pretreated with platinum. B. Massuti, M Cobo, C Camps, M Dómine, **M Provencio**, V Alberola, N Viñolas, R Rosell, M Tarón, V Gutierrez- Calderón, P Lardelli, V Alfaro, A Nieto, D Isla. *Lung Cancer* 2012, 76: 354-361. (FI: 3,36)
122. DNA damage and repair in Cancer Therapy. A López-González, P Ibeas Millán, **M Provencio**. *J Cancer Sci Ther* 2012, S8-002. Doi: 10.4172/1948-5956. (FI: 4.03 provisional)
123. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. **Provencio M**, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jiménez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sánchez A, Rosell R. *Cancer Chemother Pharmacol* 2012, sep 29. Epub ahead of print. (FI 2,88).
124. Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, **Provencio M**, Callau C, Álvaro T. *Clin Dev Immunol.* 2012;2012:756353. doi: 10.1155/2012/756353. (F.I.: 3,06)
125. Cancer-Associated Fibroblast and M2 Macrophage markers together predict outcome in Colorectal Cancer patients. Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, Gómez I, Soldevilla B, Muñoz C, **Provencio M**, Campos-Martin Y, de Herreros AG, Casal I, Bonilla F, Peña C. *Cancer Sci.* 2013 Jan 9. doi: 10.1111/cas.12096. [Epub ahead of print] (F.I.: 3, 325)
126. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group. **Provencio M**, Cruz Mora MA, Gómez Codina J, Quero Blanco C, Llanos M, García Arroyo FR, De la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; On behalf of the GOTEL (Spanish Lymphoma

- Oncology Group). *Leuk Lymphoma*. 2013 Apr 11. [Epub ahead of print].(F.I.: 2,58).
127. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, **Provencio M**, Alvarez-Vallina L, Sanz L. *Med Oncol*. 2013 Jun;30(2):572. doi: 10.1007/s12032-013-0572-1. Epub 2013 Apr 12
128. Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report. A López-González, E Almagro, C Salas, A Varela, **M Provencio**. *Respiratory Medicine Case Reports*. 2013;9: 8-10.
129. Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab.. Blesa JM, Mollá SB, Esparcia MF, Ortells JM, Godoy MP, Das AM, Magan BM, **Provencio M**, Sanchez JL, Canales JB, Candel VA. *Case Rep Oncol*. 2012 Sep;5(3):676-81. doi: 10.1159/000341852.
130. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. **Provencio M**, Sánchez A, Artal A, Sánchez Torres JM, de Castro J, Dómine M, Viñolas N, Sánchez A, Pérez FJ. *Clin Transl Oncol*. 2013 Aug;15(8):659-64. doi: 10.1007/s12094-012-0989-6. (F.I.: 1,34).
131. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I, **Provencio M**, González-Martín A, Pérez M. *Clin Transl Oncol*. 2013 Jun;15(6):477-83. doi: 10.1007/s12094-012-0953-5 (F.I.: 1,34).
132. High serum levels of VEGF-C have a positive impact on outcome of advanced diffuse large B cell lymphoma patients. Rueda A, Rifá J, Quero C, Gómez-Codina J, Murias A, García-Arroyo FR, Sabín P, Llanos M, Herrero J, Lobo F, Delgado JR, **Provencio M**; on behalf of the Spanish Lymphoma Oncology Group. *Leuk Lymphoma*. 2013 Aug 22. (F.I.: 2,58).

133. New drugs and targeted treatments in Hodgkin's lymphoma.  
**Provencio M**, Sánchez A, Sánchez-Beato M. *Cancer Treat Rev.* 2013  
 Sep 20. doi:pii: S0305-7372(13)00194-1.

## Spanish Publications

1. Septicemia por *Vibrio Vulnificus*. Hernáez J., González F., **Provencio M.**, Romera M.A., Portero M.F., Pérez Maestu R., Masa C., Martínez L. de Letona.  
*Revista Española de Microbiología Clínica* 1991,6(3):144-145.
2. Hepatocarcinoma y Cirrosis Biliar Primaria. De La Fuente J., **Provencio M**, Tebas P., Masa C., Pérez Maestu R., Martínez L. de Letona J.  
*Oncología* 1992; 15(5): 85-87
3. Cáncer y metástasis. Relación con los radicales libres. ¿ Desequilibrio entre prooxidación y antioxidación ?. Romero D., Villalba M.P., Hervás A, **Provencio M.**, Clavo B., Sanz M.  
*Oncología* 1992; 15(5):19-40.
4. Signo de Lhermitte y Cáncer. Arjona A, Corral F, López Lozano JJ, **Provencio M**  
*Medicina Clínica* 1995; 105 (12) (FI: 1,2)
5. Infección en el Paciente Oncológico. Manejo de la Fiebre Neutropénica. **Provencio M.**, López Vega J.M., Bonilla F., España P.  
*Anales de Medicina Interna* 1993; 10(3): 143-146 (FI:0,4)
6. Diagnóstico diferencial de masa pulmonar. **Provencio M.**, Bonilla F., Varela A., España P.  
*Revista Clínica Española* 1994; 194(12),:1045-46 (FI:0,7)

7. Histiocitoma fibroso maligno de hueso. Bonilla F., **Provencio M.**, Hassan Y. Hotait, España P.  
*Anales de Medicina Interna* 1995;12(1): 49-50 (FI:0,4)
8. Cardiotoxicidad y quimioterapia de intensificación. Llamas P., **Provencio M.**, Rubio A., Cabrera R., Fernández MN.  
*Sangre* 1995; 40(1): 76 (FI: 1,2)
9. BRCA1 y BRCA2: Genes de susceptibilidad para el cáncer de mama y ovario.  
Bonilla F, **Provencio M**, Cubedo R.  
*Oncología*,1996; 19 (9):361-367
10. Cáncer de mama y meningioma. Jorge M, **Provencio M**, Moreno A, Navarro F, España P.  
*Rev Senología y Patol. Mam.*1997; 10( 3):194-196
11. Tratamiento adyuvante del cáncer de colon. **Provencio M**, España P, Bonilla F.  
*Oncología* 1999; 22(6):252-264
12. Relaciones de la quimioterapia con la patología molecular. **Provencio M**  
*Oncología* 1998; 21:102- 108
13. Coincidencia de cáncer de mama y sarcoma filodes. Villanueva MJ, Navarro F, Sánchez A, **Provencio M**  
*Revista Clínica Española* 1999; 199(11) (FI=0,4)
14. Prevalencia de infección por el virus de la hepatitis C en pacientes con linfomas no Hodgkinianos. Sánchez Ruiz AC, Yebra M, Portero F, **Provencio M**, Miralles C, España P.



- Medicina Clinica* 2001; 116: 333-334. (FI=1,4)
15. Breast cancer: contribution of molecular biology to the management of the disease. Bonilla F, España P, **Provencio M**.  
*Oncología* 2001; 3:130-136.
16. Seminoma en estadio I: la difícil gestión del éxito. **Provencio M**.  
*Oncología* 2002; 25(3): 17-18 (Editorial)
17. Lesión hepática indeterminada por RNM: aportación de la PET-FDG. Ruiz G, **Provencio M**, Moreno E, Magallón R, Lapeña L, Montz R, Carreras JL.  
*Oncología*, 25: 381-385, 2002.
18. Cáncer de pulmón no microcítico localmente avanzado. **Provencio M**, Valcárcel F.  
*Revista Clínica Española* 2005; 205(8):392-4. (FI=0,4)
19. Una nueva etapa. (Editorial). **Provencio M**.  
*Oncología*, 2005, 28: 11.
20. A propósito de un caso. (Editorial). **Provencio M**.  
*Oncología*, 2005, 28(6): 11-12
21. Paciente con doble lesión pulmonar y con historia de adenocarcinoma renal.  
Carcereny E, **Provencio M**, et al.  
*Revista Clínica Española* 2004, 204(7):379-80. (FI=0,4)
22. Linfoma no hodgkin difuso de células grandes B en estadios avanzados: situación del tratamiento actual y perspectivas. **Provencio M**, Rueda A, Sabín P.  
*Oncología* 2006; 29: (10):11-13.

23. Nuevos paradigmas en el tratamiento del cáncer. Optimización del tratamiento de la anemia: nuevas evidencias. **Provencio M**, Sánchez A.  
*Rev Cancer* 2007; 21, 46-48.
24. La PER y PET-TAC en la estadificación y tratamiento del cáncer de pulmón no microcítico. **Provencio M**, Sánchez A, González C, et al.  
*Oncología* 2007; 30: 28-40.
25. Quimioterapia intensiva y rescate con precursores hematopoyéticos autólogos en el tratamiento de los linfomas no Hodgkin. **Provencio M**, Fayad LE.  
*Medicina Clínica*, 2008: 130(2): 60-5. (FI: 1,6).
26. Estado actual del tratamiento adyuvante a la cirugía en los estadios iniciales del cáncer de pulmón no microcítico. **Provencio M**, Sánchez A, Cantos B.  
*Revista Clínica Española*, 6: 302-305, 2008. (FI: 0,4)
27. Rituximab in the treatment of aggressive lymphomas. Sánchez AC, **Provencio M**.  
*Cancer and Chemotherapy Rev* 2008; 3: 44-56.
28. Hodgkin's Disease and intercurrent processes that may simulate a relapse. Sánchez A, Cantos B, Salas C, España P, **Provencio M**.  
*Clinical and Translational Oncology*. 2008;10: 439-441. (FI:1,1)
29. Circulating tumor cells in breast cancer: methodology and clinical repercussions. Gassent JM, Alberola V, Esteban E, Vidal J, Gisbert R, **Provencio M**, Laforga J, Pachmann K.  
*Clinical and Translational Oncology* 2008; 10: 399-406. (FI: 1,1)

30. Análisis farmacoeconómico de rituximab en el tratamiento de mantenimiento de los pacientes con linfoma folicular. Capote FJ, Conde E, Fernández –Rañada HM, Giraldo P, Gómez-Codina J, **Provencio M**, et al. *Farmacia Hospitalaria* 2008; 32(1): 25-34.
31. [Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine](#). Gasent JM, Alberola V, **Provencio M**, Esteban E, Martín S. *Clinical and Translational Oncology* 2009; 11(1):35-40 (FI: 1,1)
32. Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study). Tusquets I, Espinosa A, Méndez M, Gil JM, Guallar JL, Perulero N, et al. *Clin Trans Oncol* 2009; 11(4): 221-7 (FI:1,1)
33. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Felip E, Garrido P, Trigo JM, López-Brea M, Paz-Ares L, **Provencio M**, Isla D. *Clinical and Translation Oncology*. 2009;11(5):284-9. (FI: 1,1)
34. Clinical-molecular factors predicting response and Survival for tyrosine-kinase inhibitors. **Provencio M**, García-Campelo R, Isla D, De Castro J. *Clinical and Translation Oncology* 2009; 11: 428-436 (FI: 1,1)
35. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Alberola V, Carrato A, Díaz-Rubio E, Gáscon P, González-Barón M, Martín M, Alba E, Casinello J, Colomer R, Cruz JJ, Barnadas A, Camps C, Casas AM, Carulla J, Constela M, Gavilá J, Isla MD, Massuti B, **Provencio M**, Rodríguez C, Sanz J. *Clinical Translation Oncology* 2009; 11: 727-736. (FI: 1,1).
36. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Maximiano C, Sánchez AC, Cantos B, Méndez M, **Provencio M**. *Clinical Translation Oncology* 2010;12: 701-703. (FI: 1,1)
37. Rituximab monotherapy in relapsed lymphocyte-predominant hodgkin's

- lymphoma. Galán L, Sánchez AC, Cantos B, **Provencio M**.  
*Clinical Translation Oncology* 2010; 12 (5): 384-6. (FI: 1,1)
38. SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. Gómez-Codina J, Sabín Dominguez P, **Provencio M**, Rueda A, Isla DM.  
*Clin Transl Oncol* 2010; 12 (11): 765-9. (FI: 1,1)
39. SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. Rodríguez-Abreu D, Llanos M, **Provencio M**, Rueda A, Isla MD. *Clin Transl Oncol* 2010; 12 (11): 760-4 (FI: 1,1)
40. SEOM Clinical guidelines for the treatment of Hodgkin's lymphoma. Quero Blanco C, García Arroyo R, **Provencio M**, Rueda A, Isla MD. *Clin Transl Oncol* 2010; 12 (11): 753-9. (FI:1,1).
41. Experiencia con sunitinib en cáncer de próstata metastásico hormonorresistente sin respuesta a docetaxel. JM Gasent, E Grande, J Casinello, **M Provencio**, JB Laforga, V Alberola. *Actas Urológicas Españolas* 2011; 35(1): 57-60.
42. Situación actual del tratamiento de mantenimiento en cáncer. Evidencias del beneficio del mantenimiento en varios tipos de cáncer. **M Provencio**. *Clinical Translational Oncology*. 2011, 2: 1-4. (FI: 1,146)
43. PET-CT in the staging and treatment of non-small-cell lung cancer. P Ibeas, B cantos, JM Gasent, B Rodríguez, M Provencio. *Clinical Translational Oncology* 2011; 13: 368-377. (FI: 1,146)
44. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Iranzo V, Sirera R, Carrato A, Cabrera A, Jantus E, Guijarro R, Sanmartín E, Blasco A, Gil M, Gómez-Aldaraví L, González-Larriba JL, Massuti B, Velasco A, **Provencio M**, Rossell R, Camps C. *Clinical Translational Oncology*. 2011 Jun;13(6):411-8. (F.I:1,146).
45. Maintenance treatment in follicular lymphoma. **M Provencio**, A Sánchez. *Cancer and Chemotherapy Rev* 2011; 6: 179-187.
46. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?.

- M Provencio, P Sabín, J Gómez-Codina, A Rueda, M Llanos, et al. *Clin Transl Oncol* 2012; 14: 386-390.
47. Surveillance of resected non-small cell lung cancer. A López-González, P Ibeas, B Cantos, **M Provencio**. *Clin Trans Oncol* 2012; DOI 10.1007/s12094-012-0841-z
48. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. **Provencio M**, Sánchez A, Artal A, Sánchez Torres JM, de Castro J, Dómine M, Viñolas N, Sánchez A, Pérez FJ.. *Clin Transl Oncol*. 2013 Jan 29. [Epub ahead of print] (FI: 1,32)

## Books and Chapters

1. Prevención del Cáncer de Pulmón. **Provencio M**. En: “*Bases Científicas de la Medicina Preventiva*”. Ed. **Farmaindustria**, 1996, pp 157- 176. ISBN: 84-87896-10-3.
2. Consideraciones y Recomendaciones sobre Diagnóstico y Tratamiento de los tumores del aparato digestivo. Moreno E, De la Calle A, Lanóz E, Pérez-Regadera JA, España P, **Provencio M**, et al. Consejería de Sanidad y Servicios Sociales. 1996. ISBN:84-451-1145-0.
3. Sarcomas óseos. España P, **Provencio M**. En: ***Oncología Clínica***. González Barón M, Feliu J, P Zamora; Espinosa E, J de Castro eds. Mc Graw-Hill. Interamericana. 2ª edición, 1998. Pp 463-475
4. Síndrome de Vena Cava Superior. **Provencio M**. En: ***Guías de actuación en Urgencias***. M. S. Moya Mir (ed), Mc Graw-Hill-Interamericana. 112-115, 1999 . ISBN: 84-486-0209-9.
5. Nutrición y Cáncer, España P, **Provencio M**. Artículo de libro.

- Nutrición y Dietética II. Aspectos clínicos. Consuelo Boticario y Socorro Coral Calvo. Universidad Nacional de Educación a Distancia. pp 415-441, 2002. ISBN: 84-362-4231-9
6. Perspectivas futuras y terapias experimentales en la enfermedad de Hodgkin. **Provencio M**, España P, Bonilla F. En libro: Linfoma de Hodgkin: aproximación diagnóstica y terapéutica. 2006. pp 159-167. Aula Ediciones. ISBN: 84-7885-414-2
  7. Highlights del 6º Simposio Internacional sobre Linfoma de Hodgkin: 25 años de experiencia del Grupo Alemán. Canales M, **Provencio M**. En libro: Linfoma de Hodgkin: aproximación diagnóstica y terapéutica. 2006. pp169-175. Grupo Aula Ediciones. ISBN: 84-7885-414-2
  8. **Editor del libro:** Linfoma de Hodgkin: aproximación diagnóstica y terapéutica. 2006. Grupo Aula Ediciones. ISBN: 84-7885-414-2.
  9. Consenso sobre el uso de agentes eritropoyéticos en pacientes anémicos con cáncer. SEOM. Uso de los agentes eritropoyéticos en la anemia inducida por quimioterapia. Nivel de hemoglobina al inicio del tratamiento. Objetivo final de hemoglobina. **Provencio M**. pp 31-37. Prodrug Multimedia. SL. 2007. ISBN: 978-84-95972-43-9.
  10. Histología y Clínica en Cáncer de Pulmón: Lenguaje Común. Guía Práctica. Editores y Autores del libro: **Provencio M** , López-Ríos F. Mayo, 2008. ISBN: 978-84-691-4684-2. Madrid. SEOM-GECP
  11. Linfoma. **Provencio M**. En: "Novedades en la literatura Oncológica" 2007. ISBN: 978-84-612-2528-6. 2008.
  12. ¿Qué es el Linfoma de Hodgkin? **M Provencio**. 2008. Colección AEAL Explica.
  13. Linfomas T. **Provencio M**, Sánchez AC. Colección AEAL Explica.

2009

14. Sarcomas óseos. España P, **Provencio M**, Cubedo R, Salas C. En: **Oncología Clínica**. González Barón M, Feliu J, P Zamora; Espinosa E, J de Castro eds. Mc Graw-Hill. Interamericana. 3ª edición, 2010.
15. La incorporación de la innovación farmacológica en el Servicio de Oncología Médica. p 97-120. **M Provencio**. En: Gestión del Servicio de Oncología Médica. Editorial YOU&US. Germá JR Editor. ISBN: 978-693-2433-2
16. Anatomía Patológica del Cáncer no microcítico de pulmón. Sánchez A. Cantos B, **Provencio M**, capítulo de libro páginas: 21-44. En: "Cáncer no microcítico de pulmón". Biblioteca Oncológica YOU & US. A.A. 2009. ISBN: 978-84-691-8239-0.
17. Tratamiento del carcinoma no microcítico de pulmón estadio III. Sánchez A, **Provencio M**. Capítulo del libro: " Monografías de Oncología Médica 2010. Cáncer de pulmón.". Editorial YOU & US. S.A. 2010. ISBN: 978-84-692-6647-2.
18. III Concurso MIR para residentes de Oncología Médica 2010. Tumores poco frecuentes. Varón con 18 años con una masa abdominal. A. López, M. Huelves, BD Doger, M. Palka, A Ruiz Valdepeñas, **M Provencio**. Pp 162-164. LUZÁN. ISBN: 978-84-7989-636-2
19. III Concurso MIR para residentes de Oncología Médica 2010. Tumores poco frecuentes. Varón de 58 años con astenia y anemia, con múltiples antecedentes oncológicos. P Ibeas, BD Doger, A. López, M. Huelves, **M Provencio**. Pp 286-289. LUZÁN. ISBN: 978-84-7989-636-2
20. Guía Práctica Clínica para el tratamiento de pacientes con linfoma folicular en primera línea y tras la recaída. A. López-Guillermo, A Salar, A Rueda, D Caballero, **M Provencio**, M Canales. 2011
21. Cisplatin: Pharmacology, Clinical Uses and Adverse Effects. Ana López-González, Patricia Ibeas Millán, **Mariano Provencio**. In: Cisplatin: Pharmacology, Clinical Uses and Adverse Effects 159- 170. Editors: Toshiko Kojima and Yoko Morita. Nova Publishers, 2012. ISBN: 978-1-61942-359-6.

22. Linfomas B y T. Biología, clínica y tratamiento. Editores: **Mariano Provencio** y Miguel Ángel Canales. Tercera Edición. AulaMédica. ISBN-13: 978-84-7885-541-4. 2012.
23. Capítulo de libro: Linfoma difuso de células grandes, 285-299. **M Provencio**, A López Guillermo. En: Linfomas B y T. Biología, clínica y tratamiento. Tercera Edición. AulaMédica. ISBN-13: 978-84-7885-541-4. 2012.
24. Linfomas de alto grado. Linfoma Linfoblástico, 365-376. M Méndez, A Custodio, **M Provencio**. En: Linfomas B y T. Biología, clínica y tratamiento. Tercera Edición. AulaMédica. ISBN-13: 978-84-7885-541-4. 2012.
25. Editor libro: Oncología para estudiantes de Medicina. 2012. Ediciones Arán. ISBN: 978-84-92977-31-4
26. Introducción. Mortalidad e incidencia del cáncer. Conceptos generales. M Provencio, A López. 9-19. En: Oncología para estudiantes de Medicina. 2012. Ediciones Arán. ISBN: 978-84-92977-31-4
27. Etiología del cáncer. Prevención y diagnóstico precoz. A López, M Provencio. 19-25. Oncología para estudiantes de Medicina. 2012. Ediciones Arán. ISBN: 978-84-92977-31-4
28. **M Provencio**. Common treatments for lymphoma. En: Lymphomas. Essentials for clinicians. Editors: Michele Ghielmini, Silvia Montoto. Pag 25-37. ESMO 2012. ISBN: 978-88-906359-2-2.
29. Inhibidores de la tirosina cinasa como tratamiento de primera línea en el cáncer de pulmón. M. Méndez, **M Provencio**. 2013: 51-68. En Carcinoma de pulmón en no fumadores. Edita: Enric Carcereny. ICG Marge. ISBN: 978-84-15340-70-6.
30. **Editor libro**: Cancer treatments in special clinical situations. European Society Medical Oncology. ESMO Handbook series. 2013. ISBN: 978-88-906359-3-9.
31. **A López, M. Provencio**. Mechanisms of resistance to EGFR inhibitors, 155-163. In: Non-small cell lung cancer. Editor: Lina Pasquariello. Nova Science Publishers, New York, 2013. ISBN: 978-1-62417-805-4.



